The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Bioregulators

Bronchogen

A Khavinson cytogen peptide aimed at the bronchi and the respiratory tract.

3 min read 12 sources

To the product To the calculator
Vial with white powder, a blue cap and a black TPD label for Bronchogen on a white podium, next to it a chain of blue and white glass spheres as a molecule model in a bright lab
No registered trial · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

Length
4 amino acids

Ala-Glu-Asp-Leu (AEDL), a synthetic tetrapeptide12

Dosing in the rat model
1 month

after 60 days of nitrogen dioxide (model of COPD), bronchial lining back in order afterwards2

More stable DNA in the test tube
+3.1 degrees

higher melting point of DNA with Bronchogen, a sign of binding to DNA5

Human trials in the registry
0 trials

no trial with Bronchogen on ClinicalTrials.gov, as of 26 Oct 202611

  • Bronchogen is the synthetic tetrapeptide Ala-Glu-Asp-Leu (AEDL) from the Russian Khavinson programme. There it is regarded as a bioregulator for the bronchi and airways.129
  • In cell cultures from human bronchial tissue it raised markers of cell division and cell maturation, more so in aged cultures than in young ones.34
  • In rats with a COPD model the remodelling of the bronchial lining receded after one month of dosing and inflammation eased.2
  • The group explains the effect by binding to DNA. In the test tube Bronchogen made DNA more stable, on the computer it fits into transporters of the cell membrane.567
  • ClinicalTrials.gov lists no trial with Bronchogen (as of October 2026). Almost all data come from one research group. Everything here is the state of research, not a recommendation.111
Profile

Updated May 2026

Class
Short bioregulator peptide

Khavinson cytogen

Use
Subcutaneous

in mg

Target tissue
the bronchi and respiratory tract
Status
Data mostly from the Khavinson program
Sizes
20 mg

1 size in the shop

Contents 15 sections
  1. At a glance
  2. What is Bronchogen?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Dosing
  7. Injection
  8. What the research shows
  9. Research status
  10. Side effects
  11. Storage
  12. Related compounds
  13. FAQ
  14. Glossary
  15. Sources

What is Bronchogen?

Bronchogen is a short peptide from the Russian Khavinson program, which deals with tissue-specific bioregulators. These very short peptides (usually 2 to 4 amino acids) are meant to act specifically on a particular tissue, Bronchogen is aimed at the bronchi and respiratory tract.

Up front: most research comes from a single research line and mostly from Russia, large independent studies are missing.

Comparison

Same family, different building blocks

Short peptides from the Khavinson programme with their amino acid sequence according to a review. Tap a card to open its entry.

Tetrapeptide, bronchi Bronchogen AEDL
Tripeptide, lungs Chonluten EDG Tetrapeptide, heart Cardiogen AEDR Tetrapeptide, pineal gland Epitalon AEDG

The assignment to a tissue comes from the Khavinson group itself. It has not been confirmed independently. 9

How it works

The theory behind the Khavinson peptides: they are meant to act at the level of gene regulation and restart age-related declining functions of a tissue. For Bronchogen a supportive effect on the bronchi and respiratory tract is described.

How well this concept transfers to humans is little established outside the originating research.

Where it acts

Where Bronchogen acted in experiments

Tap a point or a card. All from cell and animal studies, there is no confirmed receptor.

  1. Bronchi

    COPD model (rats): fewer goblet cells and less inflammation, ciliated cells back2

    Observed in trials

Known targets7

Compound PubChem CID 11690869: two described targets, all Possible route into the cell, only modelled on the computer (docking).

Peptide transporter PepT1
Gene
SLC15A1
UniProt
P46059
ChEMBL
CHEMBL4605
Action
Possible route into the cell, only modelled on the computer (docking)
Amino acid transporter LAT1
Gene
SLC7A5
UniProt
Q01650
ChEMBL
CHEMBL4459
Action
Possible route into the cell, only modelled on the computer (docking)
Glass bronchi with air sacs, DNA helices glowing in the cells of the wall, small blue molecules moving in
Theory: action at the level of gene regulation in the airways. Symbolic image.

What you need

Supplies

2 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Bronchogen vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid

  1. Bronchogen vial

    The vial (lyophilized powder, usually 20mg).

    In the shop

  2. Water and supplies

    Bacteriostatic water, U-100 insulin syringes, alcohol swabs.

    In the shop

Reconstitution

Use the peptide calculator. A 20mg vial with 2ml water gives 10mg per ml. Just add the water to the vial and let it dissolve.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 20 mg + 2 ml = 10 mg/ml

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

Injection

The injection is subcutaneous, into the fat layer under the skin. Common spots are the abdomen (keep about two finger-widths clear of the navel), the front and the inner side of the thigh, or the back of the upper arm.

The short version:

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the spot with an alcohol swab and let it dry

  2. Pinch up a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject slowly, wait a moment, then withdraw

  5. Put the needle straight into the sharps container

Rotate the site each time so the tissue does not get irritated. Never the same spot twice in a row.

What the research shows

The Khavinson program has published numerous works on tissue-specific bioregulators over decades (overview: Khavinson, 2002), including effects on organ function and, in animal models, on lifespan. But the read must stay honest: the data come mostly from one research line, large independent studies are missing.

Sealed test tubes, each holding a fine glass bronchial tree
The data mostly come from one research group, large independent studies are missing. Symbolic image.

Research status

Where the research stands

So far Bronchogen has been studied in cell cultures, in the test tube and in rats, almost only by the Khavinson group in St Petersburg. As of 26 Oct 2026. 11

  1. Preclinical Cell cultures, DNA experiments and a rat model
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
No registered human trial and no known approval as a medicine. Bronchogen has only been studied preclinically so far.11

So far there is no registered trial in humans. 11

Side effects

  • Well tolerated in the available reports, mainly local reactions.
  • Solid, independent human safety data are limited.

Storage

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 4 to 6 months with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark

Robust, no fridge needed.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

At least 4 to 6 months with barely any loss of potency.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same common ground: all in the TPD lexicon.

Bronchogen
Chonluten Tripeptide EDG, also for the lungs and bronchi Cardiogen Tetrapeptide AEDR, heart Cartalax Tripeptide AED, cartilage Epitalon Tetrapeptide AEDG, pineal gland Vilon Dipeptide KE, immune system Vesugen Tripeptide KED, blood vessels Pinealon Tripeptide EDR, brain Thymalin Peptide mixture from the thymus

FAQ

Common questions about Bronchogen

Short answers, each backed by the sources below.

Is Bronchogen approved or studied in humans?

As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Bronchogen. A review by the Khavinson group mentions use in lung diseases, but this is not backed by registered, independently checked trials. All data shown here come from cell cultures, DNA experiments and rats.1110

What is Bronchogen made of?

Of four amino acids: alanine, glutamic acid, aspartic acid and leucine, AEDL for short. The molecular formula is C18H30N4O9. Two papers from the same group write the sequence as Ala-Asp-Glu-Leu, the reviews and PubChem list Ala-Glu-Asp-Leu.12954

What did the rat model show?

Rats repeatedly breathed nitrogen dioxide for 60 days, a model of COPD. Then they received Bronchogen for one month. The typical remodelling receded: fewer goblet cells and less squamous lining, fewer lymphocytes and less over-inflation. The ciliated cells returned. There was more secretory IgA and fewer signs of inflammation by neutrophils.2

What happens in cell cultures?

In cultures from human embryonic bronchial tissue Bronchogen raised cell maturation factors such as CXCL12 and Hoxa3, more so in aged cultures. A second paper found more Ki67 and Mcl-1 (cell division) and changed activity of genes such as NKX2-1, FOXA1, FOXA2 and MUC5AC, which matter for the bronchial lining.34

How is such a short peptide supposed to work?

The Khavinson group assumes that short peptides reach the cell nucleus and bind to DNA. In the test tube the melting point of DNA rose by 3.1 degrees with Bronchogen, in another paper it preferred stretches with the sequence CTG. On the computer Bronchogen fits into the transporters PepT1 and LAT1 of the cell membrane. Whether this happens in the body has not been shown.567

Which side effects are known?

There are no solid data because Bronchogen has never been tested in a registered human trial. Statements about good tolerability come from the research group itself.111

Who researches Bronchogen?

Almost exclusively the group around Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology and its partners. Independent confirmation by other labs is still missing.18

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Bioregulator
Term from the Khavinson programme for short peptides that are meant to target a specific tissue. Not a term used in drug approval.
Bronchial lining
Inner layer of the bronchi with ciliated cells that move mucus and particles upwards and goblet cells that make mucus.
COPD
Chronic obstructive pulmonary disease: permanently narrowed airways, often after smoking. In research it is mimicked in rats with irritant gases.
Gene regulation
Control of which genes a cell is currently reading and turning into proteins.
Goblet cells
Mucus-producing cells of the airways. In COPD their number rises and the airways fill with mucus.
Khavinson programme
Research on peptide bioregulators that Vladimir Khavinson has built up in Russia since the 1970s. Most papers come from this group.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
PepT1 and LAT1
Transporters in the cell membrane for small peptides and amino acids. Whether Bronchogen uses them has only been calculated on the computer.
Preclinical
Research before first use in humans, in cell cultures and animal models. Results cannot be transferred directly to humans.
Subcutaneous
Into the fat layer just under the skin.
Tetrapeptide
A chain of exactly four amino acids. For Bronchogen these are alanine, glutamic acid, aspartic acid and leucine.

Evidence

Sources

Show all 12 sourcesHide sources 9 Studies1 Trial registry2 Database checked 26 Oct 2026

Studies

  1. Bronchogen in a COPD model in rats

    Kuzubova et al., Bulletin of Experimental Biology and Medicine, 2015

    DOI 10.1007/s10517-015-3047-x PMID 26468022
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Cell maturation in aged cultures of bronchial cells

    Khavinson et al., Bulletin of Experimental Biology and Medicine, 2012

    DOI 10.1007/s10517-012-1664-1 PMID 22808515
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Genes and proteins of the bronchial lining in cell culture

    Khavinson et al., Lung, 2014

    DOI 10.1007/s00408-014-9620-7 PMID 25015171
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Bronchogen and the stability of DNA

    Monaselidze et al., Bulletin of Experimental Biology and Medicine, 2011

    DOI 10.1007/s10517-011-1146-x PMID 21240358
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Short peptides in the cell nucleus and their binding to DNA

    Fedoreyeva et al., Biochemistry (Moscow), 2011

    DOI 10.1134/S0006297911110022 PMID 22117547
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Transport of short peptides via PepT1 and LAT1, computer model

    Khavinson et al., Biomolecules, 2023

    DOI 10.3390/biom13030552 PMID 36979488
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  7. Review of gene regulation by short peptides

    Khavinson et al., Molecules, 2021

    DOI 10.3390/molecules26227053 PMID 34834147
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  8. Review with names and amino acid sequences of the short peptides

    Khavinson et al., International Journal of Molecular Sciences, 2022

    DOI 10.3390/ijms23147733 PMID 35887081
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  9. Review by the Khavinson group on peptides in lung diseases

    Khavinson et al., Molecules, 2020

    DOI 10.3390/molecules25194389 PMID 32987757
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)

Trial registry

  1. Search on ClinicalTrials.gov (no trial with the peptide)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Review of peptides and ageing from the Khavinson programme (PubMed record)

    Khavinson, Neuro Endocrinology Letters, 2002 (ohne DOI)

    PMID 12374906
    Checked 26 Oct 2026 via PubMed
  2. Structure of Bronchogen in PubChem

    PubChem, U.S. National Library of Medicine (CID 11690869)

    Checked 26 Oct 2026 via PubChem

In the shop

Bronchogen in the catalog

Sizes, prices and shipping times are on the product page.

To the product